Following these transactions, the reporting entities retain a significant stake in NewAmsterdam Pharma, holding a combined total of 10,686,018 shares. Despite the sales, the Forbion entities remain major stakeholders in the company, with the shares held indirectly through their joint investment vehicle, ForGrowth NAP B.V.The transactions were part of a structured plan, and the shares were sold in multiple transactions at prices within the specified ranges. The reporting entities have committed to providing full details of the transactions upon request. For deeper insights into NAMS’s valuation and comprehensive analysis, investors can access the full Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence. For deeper insights into NAMS’s valuation and comprehensive analysis, investors can access the full Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
Following these transactions, the reporting entities retain a significant stake in NewAmsterdam Pharma, holding a combined total of 10,686,018 shares. Despite the sales, the Forbion entities remain major stakeholders in the company, with the shares held indirectly through their joint investment vehicle, ForGrowth NAP B.V.The transactions were part of a structured plan, and the shares were sold in multiple transactions at prices within the specified ranges. The reporting entities have committed to providing full details of the transactions upon request. For deeper insights into NAMS’s valuation and comprehensive analysis, investors can access the full Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
Following these transactions, the reporting entities retain a significant stake in NewAmsterdam Pharma, holding a combined total of 10,686,018 shares. Despite the sales, the Forbion entities remain major stakeholders in the company, with the shares held indirectly through their joint investment vehicle, ForGrowth NAP B.V.
The transactions were part of a structured plan, and the shares were sold in multiple transactions at prices within the specified ranges. The reporting entities have committed to providing full details of the transactions upon request.
In other recent news, NewAmsterdam Pharma Co NV has seen several major developments. The company’s leading drug candidate, obicetrapib, has shown promising results in Phase 3 trials, prompting H.C. Wainwright, Scotiabank (TSX:), and Leerink Partners to issue positive ratings and increased price targets. The drug demonstrated significant reductions in LDL-C cholesterol levels and major adverse cardiovascular events.
Additionally, NewAmsterdam Pharma has suspended and terminated a previously filed Automatic Teller Machine (ATM) Prospectus related to a $150 million share sale plan. The company also restated its financial statements for the years ending 2022 and 2021 due to identified errors in the calculation of net loss per ordinary share, and welcomed new board members, Mark C. McKenna and Wouter Joustra.
Looking forward, NewAmsterdam is preparing for the Phase 3 HORIZON trial of pelacarsen in 2025 and the Phase 3 BROADWAY trial readout, expected in the fourth quarter of 2024. These are the recent developments for NewAmsterdam Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
